Hazards of Medical Glaucoma Therapy in Cataract Patients
International Journal of Current Pharmaceutical Review and Research · 31.03.2026 · 18 (03)
DOI: 10.25258/ijcpr.18.3.198 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Current Pharmaceutical Review and Research, online erschienen am 31.03.2026. Verfasst von Shivani Shivani und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Pharmacological intervention is the primary treatment for glaucoma, designed to lower intraocular pressure and avert optic nerve injury. In patients with concurrent cataract, apprehensions have emerged about the long-term safety of topical anti-glaucoma medicines, including their propensity to induce ocular surface damage and affect cataract progression.
Objective
To assess the risks linked to medical glaucoma treatment in patients with concurrent cataract, particularly regarding adverse drug reactions and the advancement of lens opacity.
Methods
A retrospective observational study was performed on 150 individuals diagnosed with both glaucoma and cataract over the course of one year. Data pertinent to demographics, categories of anti-glaucoma drugs (betablockers, prostaglandin analogs, and carbonic anhydrase inhibitors), occurrence of adverse effects, and cataract advancement status were extracted from medical records. A chi-square test was conducted to evaluate the relationship between medication type and outcomes, with a p-value of less than 0.05 being statistically significant.
Results
Adverse effects occurred in roughly 40% of individuals, predominantly manifesting as eye irritation and dryness. Despite beta-blockers and carbonic anhydrase inhibitors exhibiting a somewhat increased incidence of adverse effects, the correlation between medication type and adverse effects was not statistically significant (p = 0.56). No significant correlation was identified between the kind of anti-glaucoma medicine and cataract advancement (p = 0.75), suggesting that lens alterations were not substantially affected by medical treatment during the study period.
Conclusion
Medical treatment for glaucoma seems to be comparatively safe for patients with concurrent cataract. Mild side effects are rather prevalent; however, they do not exhibit a substantial correlation with certain drug classes. No evidence was discovered indicating that these drugs hasten cataract progression. Consistent oversight and personalized therapy are crucial for good patient management.
Zitieren
APA
Shivani, S., Verma, A., & Singh, R. K. (2026). Hazards of Medical Glaucoma Therapy in Cataract Patients. International Journal of Current Pharmaceutical Review and Research, 18(03). https://doi.org/10.25258/ijcpr.18.3.198
Vancouver
Shivani S, Verma A, Singh RK. Hazards of Medical Glaucoma Therapy in Cataract Patients. International Journal of Current Pharmaceutical Review and Research. 2026;18(03). doi:10.25258/ijcpr.18.3.198
BibTeX
@article{Shivani2026,
author = {Shivani, Shivani and Verma, Anshul and Singh, Rajiv Kumar},
title = {Hazards of Medical Glaucoma Therapy in Cataract Patients},
journal = {International Journal of Current Pharmaceutical Review and Research},
year = {2026},
volume = {18},
number = {03},
doi = {10.25258/ijcpr.18.3.198}
}
EUVIMED